NETRI launch new organ-on-chip kit powered by axoCellsTM
NETRI, the leading provider of organ-on-chip technologies for pre-clinical neuroscience discovery, have recently announced the launch of a new range of…
The Axol Blog
AXOL Blog
AAV and funding round trends in the iPSC market
iPSC models as a test bed for adeno-associated virus (AAV)-delivered…
Five key takeaways from the MPS World Summit 2023
Axol Bioscience report on the MPS World Summit 2023 On…
Stepping up in drug development: moving from primary cells to human iPSCs
In the pursuit of robust, scalable disease models, iPSCs have…
Human iPSCs: valuable models for cardiotoxicity screening
Building better human disease models with hiPSC-derived cardiomyocytes Between the FDA…
Axol CSO discusses the value of iPSCs for patient stratification
Using the power of iPSCs for patient stratification On the…
Now is the time for 2024 Budget Planning
Our scientific services team is available to listen to your…
Axol CEO Summer Review (Jan-Jun 2023)
Axol CEO, Liam Taylor, discusses his key reflections from the…
5 key takeaways from “Not Just Another NAMs Meeting 2023”
New Approach Methodologies for safety testing With increasing interest in…
Perspectives on the FDA Modernization Act 2.0 and drug discovery from Elizabeth Baker, Esq.
On the 29th of December 2022, the U.S. Congress passed…
Demonstrating physiological and pharmacological relevance of axoCellsTM atrial cardiomyocytes
To produce powerful in vitro models of atrial-specific conditions, you need mature,…
Axol demonstrates excellent compliance with the ISSCR Standards Document 2023
The International Society for Stem Cell Research (ISSCR) recently published…
Moving towards in vitro from a regulatory perspective: Considerations from the FDA Modernization Act 2.0
Interview with Simon Hoffman, Regulatory Consultant. Simon Hoffman is a…
